老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
GSK plc ADRhedged
70.64
0.0000
成交量：
8
成交額：
556.80
市值：
70.64萬
市盈率：
- -
高：
70.64
開：
70.64
低：
70.64
收：
70.64
52周最高：
85.03
52周最低：
56.03
股本：
1.00萬
流通股本：
1.00萬
量比：
0.25
換手率：
0.08%
股息：
2.08
股息率：
2.94%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
葛蘭素史克(GSK)股票4月29日盤中下跌5.22%：關鍵驅動因素揭曉
TradingKey中文
·
04/30
英國頭部藥企利潤意外大增，儘管行業受美國政策衝擊
环球市场播报
·
04/29
葛蘭素史克Q1業績超市場預期，預計全年盈利增長7%至9%
老虎资讯综合
·
04/29
從「抗艾第一股」到小核酸新貴 前沿生物股價與業績齊飛 靠GSK千萬美元授權金逆勢漲停
时代财经
·
04/27
葛蘭素史克(GSK.US)Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市
智通财经
·
04/17
GSK撤回被特朗普和小肯尼迪吹捧為自閉症潛在療法的藥物申請
环球市场播报
·
04/10
超長效呼吸生物製劑德莫奇單抗獲批新適應症
南方财经网
·
04/08
葛蘭素史克(GSK.US)超長效單抗新藥新適應症在中國獲批上市
智通财经
·
04/03
三星生物製劑2.8億美元收購葛蘭素史克美國工廠
环球市场播报
·
04/01
葛蘭素史克德莫奇單抗獲批上市，系中國首款治療嗜酸性表型重度哮喘的超長效生物製劑
北京商报
·
03/31
曾長期缺貨，葛蘭素史克乙肝疫苗安在時重返中國市場
红星资本局
·
03/26
葛蘭素史克(GSK)股票3月25日盤中上漲3.49%：釋放什麼信號？
TradingKey中文
·
03/26
GSK與上藥科園貿易就乙肝疫苗安在時啓動戰略合作
南方财经网
·
03/25
葛蘭素史克向中國發展高層論壇2026年年會提交專題報告
中国经济网
·
03/23
跨國藥企集體「加倉」中國：一場超千億元的信任投票
21世纪经济报道
·
03/23
蛇串瘡百億級市場的「冰與火」：GSK全球市場「獨舞」 百克生物遭遇「極寒」
华夏时报网
·
03/21
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/GSKH/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":70.6364,"timestamp":1789653836042,"preClose":70.6364,"halted":0,"volume":8,"delay":0,"changeRate":0,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-17 10:05:43 EDT","open":70.6364,"high":70.6364,"low":70.6364,"amount":556.800048,"amplitude":0,"askPrice":71.39,"askSize":100,"bidPrice":69.74,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":70.6364,"nav":69.73341,"aum":697403.83341,"dividendRate":0.0294,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":70.55,"preClose":70.6364,"latestTime":"16:10 EDT","volume":6,"amount":423.8184,"timestamp":1789589404176,"change":-0.0864,"changeRate":-0.001223,"amplitude":0},"volumeRatio":0.252967,"impliedVol":0.1632,"impliedVolPercentile":0.2735},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.252967,"shares":10001,"dividePrice":2.0767,"high":70.6364,"amplitude":0,"preClose":70.6364,"low":70.6364,"week52Low":56.03,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":70.6364,"eps":0,"divideRate":0.0294,"volume":8,"delay":0,"ttmEps":0,"open":70.6364,"prevYearClose":68.2031,"prevWeekClose":66.9705,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":67.0681,"twentyDayClose":73.0903,"sixtyDayClose":73.662},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631440005","title":"葛蘭素史克(GSK)股票4月29日盤中下跌5.22%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2631440005","media":"TradingKey中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631440005?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 01:17","pubTimestamp":1777483043,"startTime":"0","endTime":"0","summary":"• 尽管销售强劲并重申了业绩指引，GSK股价仍出现下跌。\n• 每股收益低于分析师预期，引发了市场的负面反应。\n• 法律拨备及对老牌药物的担忧影响了投资者信心。","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/261838095-market-movers-gsk-20260429","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4007","GSKH","BK4588","GSK.UK","GSK","BK4585","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631910535","title":"英國頭部藥企利潤意外大增，儘管行業受美國政策衝擊","url":"https://stock-news.laohu8.com/highlight/detail?id=2631910535","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631910535?lang=zh_tw&edition=fundamental","pubTime":"2026-04-29 18:15","pubTimestamp":1777457700,"startTime":"0","endTime":"0","summary":"英国两大药企阿斯利康与葛兰素史克周三公布 2026 年一季度核心盈利均超预期，开局向好。欧洲多家药企高管近期警示：特朗普政府推行最惠国待遇药价政策，将美国药价与他国低价挂钩，欧洲或面临新药上市减少的风险。 英国市值第二大公司阿斯利康与第九大公司葛兰素史克周三早盘公布一季度利润，双双超出市场预期。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-29/doc-inhwefuw7976588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","BK4588","GSK","GSKH","LU1829250122.USD","GSK.UK","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129840658","title":"葛蘭素史克Q1業績超市場預期，預計全年盈利增長7%至9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129840658","media":"老虎资讯综合","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129840658?lang=zh_tw&edition=fundamental","pubTime":"2026-04-29 14:09","pubTimestamp":1777442988,"startTime":"0","endTime":"0","summary":"4月29日，$葛兰素史克(GSK)$盘后一度涨超6%，随后快速回落！该公司第一季度营收76.3亿英镑，预估76.1亿英镑；第一季度调整后每股收益46.5便士，预估43.2便士。预计全年销售额（按固定汇率计算）增长3%至5%；预计全年调整后每股收益增长7%至9%；预计全年调整后营业利润增长7%至9%；预计2031年销售额将超过400亿英镑。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ca0e3dea87604e6a95a3bf5695c5bcab","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葛兰素史克Q1业绩超市场预期，预计全年盈利增长7%至9%","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225284248.USD","LU2646069778.SGD","IE00BQJZX424.USD","BK4588","LU0225771236.USD","BK4532","IE0034235071.USD","LU0321505439.SGD","LU1487256676.USD","LU0971552673.USD","LU1302929846.USD","LU0545562505.USD","LU0058720904.USD","BK4585","LU0211331839.USD","SG9999001176.USD","GSKH","LU1400636491.USD","LU1481599808.USD","LU0306806265.USD","GSK","LU0203347892.USD","LU0289739699.SGD","LU1064927863.SGD","LU1202635105.USD","LU1670756490.USD","LU0109981661.USD","LU1983299246.USD","LU0971552830.HKD","LU1035777561.USD","LU0987226296.USD","SGXZ57979304.SGD","LU1309081286.SGD","LU1046248800.SGD","LU1645745479.HKD","LU1098665638.USD","SG9999001176.SGD","LU1829250122.USD","LU0557290698.USD","LU0203345920.USD","LU1015430645.USD","SG9999013999.USD","LU1400636574.HKD","BK4007","LU0575583348.USD","LU1400636657.SGD","IE00BWDBJ516.SGD","LU1481600234.SGD","LU0225283273.USD","LU0985481810.HKD","LU0321505868.SGD","BK5011","LU0306807586.USD","LU1228905540.USD","LU1228905037.USD","LU0161305163.EUR","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393046","title":"從「抗艾第一股」到小核酸新貴 前沿生物股價與業績齊飛 靠GSK千萬美元授權金逆勢漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393046","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630393046?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 18:46","pubTimestamp":1777286760,"startTime":"0","endTime":"0","summary":"4月27日，在医药股普遍承压、板块整体走弱的背景下，创新药企前沿生物（688221.SH）却逆势爆发，开盘后快速拉升触及20%的涨停板，截至收盘，前沿生物涨停封板，报22.74元/股。前沿生物成立于2003年，创始人谢东出生于1966年，曾领导和参与了多个艾滋病新药的全球开发与上市工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720433081.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720433081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","BK4532","688221","GSK","BK0239","BK4588","GSK.UK","BK4007","LU1829250122.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628064279","title":"葛蘭素史克(GSK.US)Belantamab mafodotin(瑪貝蘭妥單抗)在華獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2628064279","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628064279?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 16:39","pubTimestamp":1776415186,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月17日，国家药监局(NMPA)网站显示，葛兰素史克(GSK.US)的Belantamab mafodotin(玛贝兰妥单抗)在华获批上市。根据此前的优先审评信息，此次获批的适应症为联合硼替佐米和地塞米松治疗既往接受过至少一种治疗的多发性骨髓瘤成人患者。玛贝兰妥单抗是Seagen(已被辉瑞收购)开发的一款BCMA ADC。2009年12月，GSK与Seagen达成协议，获得该药物的研究、开发、生产和商业化权益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GSKH","BK4585","LU1829250122.USD","IPOS","GSK.UK","BK4007","GSK","BK4532","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626713798","title":"GSK撤回被特朗普和小肯尼迪吹捧為自閉症潛在療法的藥物申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2626713798","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626713798?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 03:23","pubTimestamp":1775762580,"startTime":"0","endTime":"0","summary":"葛兰素史克已于4月9日撤回了其叶酸类药物Wellcovorin的一项申请。该药物曾被特朗普政府及卫生与公众服务部部长小罗伯特·F·肯尼迪吹捧为自闭症的潜在治疗选择。 然而，FDA明确表示，该批准不适用于自闭症的治疗。当时，卫生部长小肯尼迪称亚叶酸钙是一种“令人兴奋的疗法”，可能对自闭症儿童有益。 据报道，GSK已撤回了相关申请。 据统计，脑叶酸缺乏症的发病率约为百万分之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-10/doc-inhtxusp5562710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSK.UK","GSK","BK4007","BK4532","BK4585","BK4588","LU1829250122.USD","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625915966","title":"超長效呼吸生物製劑德莫奇單抗獲批新適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2625915966","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625915966?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 15:36","pubTimestamp":1775633787,"startTime":"0","endTime":"0","summary":"南方财经4月8日电，葛兰素史克（LSE/NYSE:GSK）今日宣布，中国国家药品监督管理局（NMPA）批准易适来?（德莫奇单抗）与鼻用糖皮质激素联合使用，治疗系统性糖皮质激素和/或手术治疗无法充分控制疾病的慢性鼻窦炎伴鼻息肉（CRSwNP）成人患者。这些患者在接受系统性糖皮质激素和/或手术后，病情仍未得到充分控制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604083698007473.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604083698007473.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSKH","BK4532","GSK","BK4588","GSK.UK","BK4007","LU1829250122.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624765321","title":"葛蘭素史克(GSK.US)超長效單抗新藥新適應症在中國獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2624765321","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624765321?lang=zh_tw&edition=fundamental","pubTime":"2026-04-03 15:51","pubTimestamp":1775202696,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月3日，NMPA官网显示，葛兰素史克“德莫奇单抗”新适应症获批上市，用于治疗慢性鼻窦炎伴鼻息肉病。2025年12月，德莫奇单抗在美国迎来全球首批。2026年3月，德莫奇单抗首次登陆中国市场。本次是德莫奇单抗在国内获批的第 2 项适应症。GSK拥有实力雄厚、行业领先的呼吸产品管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"葛兰素史克(GSK.US)超长效单抗新药新适应症在中国获批上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1829250122.USD","GSK","GSK.UK","BK4585","BK4007","GSKH","BK4532","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624561681","title":"三星生物製劑2.8億美元收購葛蘭素史克美國工廠","url":"https://stock-news.laohu8.com/highlight/detail?id=2624561681","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624561681?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 13:12","pubTimestamp":1775020320,"startTime":"0","endTime":"0","summary":"三星集团旗下生物技术公司三星生物制剂周三表示，已斥资 2.8 亿美元收购了英国制药巨头葛兰素史克在美国的一家工厂。 三星生物制剂公司在一份新闻稿中表示，位于马里兰州罗克维尔的这家工厂拥有6万升原料药的生产能力，使该公司的总产能达到84.5万升。 三星生物制剂表示，计划进一步投资以扩大工厂产能并升级技术，从而巩固其加强全球供应链和改善关键药物可及性的长期承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-01/doc-inhsynau2671180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GSK.UK","BK4588","GSK","BK4007","BK4532","GSKH","LU1829250122.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623001503","title":"葛蘭素史克德莫奇單抗獲批上市，系中國首款治療嗜酸性表型重度哮喘的超長效生物製劑","url":"https://stock-news.laohu8.com/highlight/detail?id=2623001503","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623001503?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 17:54","pubTimestamp":1774950879,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）葛兰素史克近日宣布，中国国家药品监督管理局批准易适来（德莫奇单抗）用于成人和12岁及以上青少年重度嗜酸性粒细胞性哮喘的维持治疗。据了解，易适来获批用于重度哮喘的治疗是基于SWIFT-1和SWIFT-2两项Ⅲ期临床试验的研究数据。在这两项均联合标准治疗的研究中，相较于安慰剂组，德莫奇单抗每年给药两次，能持续减少哮喘急性发作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690543314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690543314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","BK4007","LU1829250122.USD","BK4585","GSK","BK4532","GSKH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622850002","title":"曾長期缺貨，葛蘭素史克乙肝疫苗安在時重返中國市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2622850002","media":"红星资本局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622850002?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 20:36","pubTimestamp":1774528560,"startTime":"0","endTime":"0","summary":"红星资本局3月26日消息，一款在2022年就被传出缺货的进口乙肝疫苗，宣布重返中国市场。3月25日，葛兰素史克（GSK）宣布与科园信海（北京）医疗用品贸易有限公司（简称“上药科园贸易”）就乙肝疫苗安在时（EngerixB，重组乙型肝炎疫苗（酿酒酵母））启动战略合作。GSK表示，2026年正值安在时全球上市40周年，此次重返中国市场是满足市场需求的有力举措。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263685856696.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685856696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4614","GSK","LU0963586101.USD","BK4007","LU1829250122.USD","BK4588","ASHR","GSK.UK","GSKH","CQQQ","BK4532","BK4585","KWEB","ASHS","BK4504","DRAG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622001523","title":"葛蘭素史克(GSK)股票3月25日盤中上漲3.49%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001523","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001523?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 03:17","pubTimestamp":1774466226,"startTime":"0","endTime":"0","summary":"• GSK的RSV疫苗获FDA扩大批准，适用于高风险成年人群。\n• 一款在研抗癌药物在日本获得孤儿药认定。\n• 分析师维持“买入”评级，理由是不确定性缓解和增长指引。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/Market-Movers/261720384-market-movers-gsk-20260325","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSK","GSKH","BK4588","LU1829250122.USD","BK4007","BK4585","GSK.UK","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622029595","title":"GSK與上藥科園貿易就乙肝疫苗安在時啓動戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2622029595","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622029595?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 16:48","pubTimestamp":1774428480,"startTime":"0","endTime":"0","summary":"南方财经3月24日电，记者获悉，今日，葛兰素史克（GSK）与上药科园贸易宣布双方将基于既有疫苗业务合作的良好基础之上，就GSK旗下乙肝疫苗安在时?（EngerixB，通用名：重组乙型肝炎疫苗(酿酒酵母)）开展深层次的协同与商业模式创新。本次合作模式不仅是单一的进口与分销安排，更是一个以市场协同和规模化覆盖为核心的战略型商业合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603253684092524.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684092524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","LU1829250122.USD","GSKH","BK4007","GSK.UK","GSK","BK4585","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777224","title":"葛蘭素史克向中國發展高層論壇2026年年會提交專題報告","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777224","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621777224?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 14:38","pubTimestamp":1774247880,"startTime":"0","endTime":"0","summary":"3月22日至23日，中国发展高层论坛2026年年会在北京举行。葛兰素史克(GSK)向年会提交专题报告《健康优先战略下的价值转型：以乙肝功能性治愈为突破口，从“被动治疗”迈向“主动健康”》。当 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260323/c675476004.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260323/c675476004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["GSKH","BK4532","GSK","BK4588","GSK.UK","BK4007","LU1829250122.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621724755","title":"跨國藥企集體「加倉」中國：一場超千億元的信任投票","url":"https://stock-news.laohu8.com/highlight/detail?id=2621724755","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621724755?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 13:13","pubTimestamp":1774242780,"startTime":"0","endTime":"0","summary":"在阿斯利康宣布计划于2030年前在中国投资逾1000亿元人民币（150亿美元），以扩大在药品生产与研发领域的布局后，多家跨国药企（MNC）接连宣布加大中国市场投资。近日，中国发展高层论坛2026年年会现场涌动着一股“MNC投资热度”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603233680398150.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233680398150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","GSKH","BK4585","BK4007","LU1829250122.USD","BK4532","GSK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621520765","title":"蛇串瘡百億級市場的「冰與火」：GSK全球市場「獨舞」 百克生物遭遇「極寒」","url":"https://stock-news.laohu8.com/highlight/detail?id=2621520765","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621520765?lang=zh_tw&edition=fundamental","pubTime":"2026-03-21 10:20","pubTimestamp":1774059600,"startTime":"0","endTime":"0","summary":"春寒料峭谨防“会呼吸的痛”。随着春季气温波动，病毒进入活跃期，流行病传染病高发。带状疱疹，这个民间俗称“蛇串疮”的疾病，正以极高发病率威胁着大众健康。2025年发布的《中国带状疱疹疾病负担与经济学评价研究》显示，带状疱疹新发病例呈现年轻化，全人群终身发病风险超过30%。而与庞大市场需求形成鲜明对比的是，国内疫苗接种率的持续低迷。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603213679560322.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603213679560322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1829250122.USD","GSKH","GSK","BK4532","BK4585","GSK.UK","BK4007","BK0239","688276","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":5,"totalSize":96,"code":"91000000","status":"200"}]}}